The Budget Impact Of An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk: Estimated Impact On Unscheduled Healthcare Costs And Inhaler Satisfaction

Nicolai, J; Torvinen, Saku; Howard, DJ; Miles, Richard W.; Greaney, Máire; Comberiati, U; Plich, A

doi:10.1016/j.jval.2015.09.1393

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their model also anticipated a total drug cost savings of €53.66 million and additional savings of €4.12 million because of the progression in inhalation technique. Regarding other inhalation devices, Nicolai et al 40 assessed the potential economic impact of introducing an inhaler with improved features compared to Spiriva ® Handihaler ® to treat COPD in the UK. The potential budgetary impact achieved by using the new inhaler instead of Handihaler is calculated as €104.91 per patient and €16.69 million for the UK COPD population per year.…”

Section: Discussionmentioning

confidence: 99%

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Darbà¹,

Ramírez²,

García-Rivero³

et al. 2017

CEOR

View full text Add to dashboard Cite

ObjectiveThe objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia.MethodsA 4-year budget impact model was developed for the time period of 2015–2018. This study aimed at evaluating the budget impact associated with the introduction of DuoResp Spiromax in comparison with Symbicort® Turbuhaler® and Rilast® Turbuhaler. National and regional data on COPD prevalence were obtained from the literature. Input data on health care resource utilization were obtained by clinical consultation. Resource included primary care visits, specialist visits, hospitalization, and emergency room visits as well as the length of hospital stay. Based on both pharmacological and health care resource costs, overall annual treatment cost per patient was estimated in EUR 2015.ResultsIt was calculated that 130,777 adults were treated with budesonide/formoterol FDC delivered by a dry powder inhaler, Turbuhaler, in Spain in 2015. However, the target population decreases over the next 4 years. This pattern was observed in 4 regions, but for Andalusia, the treated population increased slightly. The overall budget savings in Spain with the market share of DuoResp Spiromax were estimated to be €6.01 million for the time period of 2015–2018. Region-specific data resulted in savings of €902,133 in Andalusia, €740,520 in Catalonia, €464,281 in Galicia, €748,996 in Madrid, and €495,812 in Valencia for the time period of 2015–2018.ConclusionThe introduction of budesonide/formoterol FDC delivered by Spiromax for COPD treatment is likely to contribute in a reduction of health care costs for Spain and in 5 Spanish regions. This model forecasts that Spain and these 5 Spanish regions were likely to have savings, which might be due to fewer days of hospitalization, avoided emergency room, and primary care visits.

show abstract

Section: Discussionmentioning

confidence: 99%

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax® compared with Turbuhaler® in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Darbà¹,

Ramírez²,

García-Rivero³

et al. 2017

CEOR

View full text Add to dashboard Cite

show abstract

The Budget Impact Of An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk: Estimated Impact On Unscheduled Healthcare Costs And Inhaler Satisfaction

Cited by 1 publication

References 0 publications

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>® </sup>compared with Turbuhaler<sup>® </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>® </sup>compared with Turbuhaler<sup>® </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Contact Info

Product

Resources

About

The Budget Impact Of An Inhaler With Improved Features Compared To Spiriva® Handihaler® For The Management Of Chronic Obstructive Pulmonary Disease (Copd) In The Uk: Estimated Impact On Unscheduled Healthcare Costs And Inhaler Satisfaction

Cited by 1 publication

References 0 publications

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>&reg; </sup>compared with Turbuhaler<sup>&reg; </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>&reg; </sup>compared with Turbuhaler<sup>&reg; </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Contact Info

Product

Resources

About

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>® </sup>compared with Turbuhaler<sup>® </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax<sup>® </sup>compared with Turbuhaler<sup>® </sup>in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain